Activity type and examples. by Lan Li (73597)

Subjects:

Change of proportions between phases and statistical test results (corresponding to Figs 2–4). by Lan Li (73597)

Subjects:

Stacked bar showing the frequency and mode changes of ten activities (1–5) across 7 phases; the modes in phase 0 were assumed to be all doing in-person. by Lan Li (73597)

Subjects:

Early IOP lowering response following injection with ssAAV2-STC-1-FLAG. by Gavin W. Roddy (7320446)

“…After an initial, non-significant decrease in IOP in both ssAAV2-STC-1-FLAG treated mice and ssAAV2-GFP control mice at day 1, and a return to baseline with ssAAV2-GFP by day 2, significant IOP lowering was seen following treatment with ssAAV2-STC-1-FLAG starting at day 2. …”

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Number of phylogroups occurring in individuals. by Rasel Barua (768634)

“…The present study suggests that particular phylogroups and STs are likely to dominate in different locations in the lower gut of humans.</p></div>…”

Accuracy metrics with different percentage of the training dataset. by Saravanan Manoharan (21273304)

Subjects:

Average starting HR decreases as classes occur later during the morning. by Diana K. Darnell (8067143)

Concentration of RebA and Steviol showed increased significantly, whereas stevioside showed significant decrease in all the transgenic lines. by Nazima Nasrullah (6874496)

Implicit and explicit task correlations. by Talia L. Retter (16520742)

Significant adaptations in gut composition occur during and after chemoradiotherapy. by Molly B. El Alam (10231830)

Immunostaining of lungs from a control mouse and a mouse infected with SARS-CoV-2. by Germán Ricardo Magaña-Ávila (18446799)

Subjects:

Degeneration Saline group presented with significant decreased final weight in relation to other groups. by Flavia Gomes Velasque Gama (21175112)

Study flowchart for enrollment in the trial cohort and the validation cohort. by Kumiko Shirai (13014884)

Subjects:

The results of serum SAP and PPBP measurements in patients with chronic hepatitis C. by Kumiko Shirai (13014884)

Subjects:

Serum SAP and PPBP levels in patients with chronic hepatitis B and patients with NAFLD. by Kumiko Shirai (13014884)

Subjects:

Changes after HCV elimination. by Kumiko Shirai (13014884)

Subjects:

The relative quantitative values of 3 SAP-targeted peptides and 1 PPBP-targeted peptide. by Kumiko Shirai (13014884)

Subjects:

The receiver operating characteristic curve analysis of IVLGQEDSYGGK, DNELLVYK, AYSLFSYNTQGR, and ICLDPDAPR. by Kumiko Shirai (13014884)

Subjects:

Results of statistical comparisons of AUCs for diagnosing each liver fibrosis stage. by Kumiko Shirai (13014884)

Subjects: